OncoMed Pharmaceuticals To Present At The Cowen And Company 34th Annual Health Care Conference

REDWOOD CITY, Calif., Feb. 28, 2014 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Paul J. Hastings, OncoMed's Chairman and Chief Executive Officer, will speak at the Cowen and Company 34th Annual Health Care Conference being held at the Boston Marriott Copley Place in Boston, MA.

Mr. Hastings will make a presentation on March 3, 2014 beginning at 1:30 pm ET. To access the live webcast and subsequent archived recording for the presentation, please visit the Investors tab on the OncoMed website at www.oncomed.com.

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells. OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (Anti-DLL4, OMP-21M18), OMP-59R5 (Anti-Notch2/3), OMP-52M51 (Anti-Notch1), vantictumab (Anti-Fzd7, OMP-18R5), and OMP-54F28 (Fzd8-Fc), which target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed has two other antibodies in preclinical development, Anti-DLL4/Anti-VEGF bispecific and Anti-RSPO3, with Investigational New Drug filings planned for late 2014 or early 2015. OncoMed is also pursuing discovery of additional novel anti-CSC product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.
CONTACT: Investor Contact:         OncoMed Pharmaceuticals         Shari Annes         Investor Relations         (650) 888-0902         shari.annes@oncomed.com                  Media Inquiries:         BCC Partners         Karen L. Bergman or         Michelle Corral         (650) 575-1509 or (415) 794-8662         kbergman@bccpartners.com or         mcorral@bccpartners.com

OncoMed Pharmaceuticals, Inc. Logo

More from Press Releases

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling

21st Century Fox Scoops Up Local News Stations

21st Century Fox Scoops Up Local News Stations

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Walmart CEO: 'We Are Transforming Globally' With Flipkart

Three-Part FREE Webinar Series

Three-Part FREE Webinar Series

March 24 Full-Day Course Offering: Professional Approach to Trading SPX

March 24 Full-Day Course Offering: Professional Approach to Trading SPX